|Bid||169.1200 x 100|
|Ask||169.1600 x 100|
|Day's Range||168.7600 - 169.9078|
|52 Week Range||133.6400 - 184.2100|
|PE Ratio (TTM)||16.08|
|Dividend & Yield||4.60 (2.74%)|
|1y Target Est||N/A|
Regeneron Pharmaceuticals has launched three new drugs that could kick-start sales growth over the coming years.
Biotech has underperformed the broader market this month, but Jefferies' Michael Yee writes that that's not really a concern--or a surprise. A little more detail about each: AMGN: key incoming questions around scenarios for upcoming REGN injunction appeals decision where buyside consensus is for majority likelihood AMGN wins with some pot'l for court trying to force a financial settlement w/ large royalty (worth $2-3/share). If AMGN loses, there shouldn't be any change to estimates given consensus has not adjusted any 2018+ PCSK9 numbers for a win though AMGN already won the initial federal injunction decision.
The companies will also have a deep focus into specific therapeutic areas